Wet Age-Related Macular Degeneration (Wet AMD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Wet Age-Related Macular Degeneration (Wet AMD) markets reached a value of US$ 8,997.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 16,864.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.9% during 2024-2034.
Wet Age-Related Macular Degeneration (Wet AMD) market is currently driven by factors such as a rising patient pool, improving diagnosis and drug treatment rates, an increase in the ageing population and improving efficacy of current and emerging therapies, etc. Wet Age-Related Macular Degeneration is an eye disease that destroys the macula, which is part of the retina at the back of the eye. Wet AMD involves the growth of abnormal blood vessels under the macula that leak blood and fluids into layers of the retina, including the macula. The symptoms of wet AMD usually start suddenly and are often severe. If a patient has wet AMD in one eye, it’s extremely likely that he will also get it in the other eye. With wet AMD, leaked blood and fluids can cause scar tissue to form and damage cells in the retina, damaging the central vision. Wet AMD can cause severe vision loss but does not lead to total blindness since a patient can retain his side vision. Having wet AMD can, however, make it extremely hard for people to do their daily things and can negatively impact the quality of their life.
Although the cause of Wet Age-Related Macular Degeneration is still largely unknown, age represents an important risk factor for developing Wet AMD. The disease is most common in people over 50 and becomes even more common in their 70s and 80s. Furthermore, smoking doubles the probability of developing wet AMD. In addition to cutting off oxygen to the eyes, researchers have found that smoking may damage cells and make it more difficult for nutrients to reach the eyes through the bloodstream. Other risk factors include gender, race, family history, heart disease, obesity etc.
IMARC Group’s new report 'Wet Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast' provides an exhaustive analysis of the Wet Age-Related Macular Degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Wet Age-Related Macular Degeneration market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Wet Age-Related Macular Degeneration across the seven major markets. According to the report, the United States has the largest patient pool for Wet Age-Related Macular Degeneration and also represents the largest market for Wet Age-Related Macular Degeneration treatments. Furthermore, the current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Wet Age-Related Macular Degeneration market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Wet Age-Related Macular Degeneration Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Wet Age-Related Macular Degeneration Market
Sales of Various Drugs Across the Wet Age-Related Macular Degeneration Market
Reimbursement Scenario in the Wet Age-Related Macular Degeneration Market
Competitive Landscape:
This report also provides a detailed analysis of the current Wet Age-Related Macular Degeneration marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Wet Age-Related Macular Degeneration market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Wet Age-Related Macular Degeneration market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Wet Age-Related Macular Degeneration market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Wet Age-Related Macular Degeneration market?
Epidemiology Insights
What is the size of the Wet Age-Related Macular Degeneration patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Wet Age-Related Macular Degeneration across the seven major markets?
What are the key factors driving the epidemiological trend of Wet Age-Related Macular Degeneration?
What will be the growth rate of Wet Age-Related Macular Degeneration patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Wet Age-Related Macular Degeneration drugs and what are their market performance?
What are the key pipeline Wet Age-Related Macular Degeneration drugs and how are they expected to perform in the coming years?
How safe are the current marketed Wet Age-Related Macular Degeneration drugs and what are their efficacies?
How safe are the late-stage pipeline Wet Age-Related Macular Degeneration drugs and what are their efficacies?
What are the current treatment guidelines for Wet Age-Related Macular Degeneration drugs across the seven major markets?
Who are the key companies in the Wet Age-Related Macular Degeneration market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Wet Age-Related Macular Degeneration market?
Wet Age-Related Macular Degeneration (Wet AMD) market is currently driven by factors such as a rising patient pool, improving diagnosis and drug treatment rates, an increase in the ageing population and improving efficacy of current and emerging therapies, etc. Wet Age-Related Macular Degeneration is an eye disease that destroys the macula, which is part of the retina at the back of the eye. Wet AMD involves the growth of abnormal blood vessels under the macula that leak blood and fluids into layers of the retina, including the macula. The symptoms of wet AMD usually start suddenly and are often severe. If a patient has wet AMD in one eye, it’s extremely likely that he will also get it in the other eye. With wet AMD, leaked blood and fluids can cause scar tissue to form and damage cells in the retina, damaging the central vision. Wet AMD can cause severe vision loss but does not lead to total blindness since a patient can retain his side vision. Having wet AMD can, however, make it extremely hard for people to do their daily things and can negatively impact the quality of their life.
Although the cause of Wet Age-Related Macular Degeneration is still largely unknown, age represents an important risk factor for developing Wet AMD. The disease is most common in people over 50 and becomes even more common in their 70s and 80s. Furthermore, smoking doubles the probability of developing wet AMD. In addition to cutting off oxygen to the eyes, researchers have found that smoking may damage cells and make it more difficult for nutrients to reach the eyes through the bloodstream. Other risk factors include gender, race, family history, heart disease, obesity etc.
IMARC Group’s new report 'Wet Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast' provides an exhaustive analysis of the Wet Age-Related Macular Degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Wet Age-Related Macular Degeneration market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Wet Age-Related Macular Degeneration across the seven major markets. According to the report, the United States has the largest patient pool for Wet Age-Related Macular Degeneration and also represents the largest market for Wet Age-Related Macular Degeneration treatments. Furthermore, the current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Wet Age-Related Macular Degeneration market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Wet Age-Related Macular Degeneration Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Wet Age-Related Macular Degeneration Market
Sales of Various Drugs Across the Wet Age-Related Macular Degeneration Market
Reimbursement Scenario in the Wet Age-Related Macular Degeneration Market
Competitive Landscape:
This report also provides a detailed analysis of the current Wet Age-Related Macular Degeneration marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Wet Age-Related Macular Degeneration market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Wet Age-Related Macular Degeneration market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Wet Age-Related Macular Degeneration market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Wet Age-Related Macular Degeneration market?
Epidemiology Insights
What is the size of the Wet Age-Related Macular Degeneration patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Wet Age-Related Macular Degeneration across the seven major markets?
What are the key factors driving the epidemiological trend of Wet Age-Related Macular Degeneration?
What will be the growth rate of Wet Age-Related Macular Degeneration patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Wet Age-Related Macular Degeneration drugs and what are their market performance?
What are the key pipeline Wet Age-Related Macular Degeneration drugs and how are they expected to perform in the coming years?
How safe are the current marketed Wet Age-Related Macular Degeneration drugs and what are their efficacies?
How safe are the late-stage pipeline Wet Age-Related Macular Degeneration drugs and what are their efficacies?
What are the current treatment guidelines for Wet Age-Related Macular Degeneration drugs across the seven major markets?
Who are the key companies in the Wet Age-Related Macular Degeneration market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Wet Age-Related Macular Degeneration market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 WET AGE-RELATED MACULAR DEGENERATION - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 WET AGE-RELATED MACULAR DEGENERATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 WET AGE-RELATED MACULAR DEGENERATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 WET AGE-RELATED MACULAR DEGENERATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Wet Age-Related Macular Degeneration Guidelines, Management and Treatment
8.2 Wet Age-Related Macular Degeneration Treatment Algorithm
9 WET AGE-RELATED MACULAR DEGENERATION - UNMET NEEDS
10 WET AGE-RELATED MACULAR DEGENERATION - KEY ENDPOINTS OF TREATMENT
11 WET AGE-RELATED MACULAR DEGENERATION - MARKETED PRODUCTS
11.1 List of Wet Age-Related Macular Degeneration Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 WET AGE-RELATED MACULAR DEGENERATION - PIPELINE DRUGS
12.1 List of Wet Age-Related Macular Degeneration Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. WET AGE-RELATED MACULAR DEGENERATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 WET AGE-RELATED MACULAR DEGENERATION - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Wet Age-Related Macular Degeneration - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Wet Age-Related Macular Degeneration - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Wet Age-Related Macular Degeneration - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Wet Age-Related Macular Degeneration - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Wet Age-Related Macular Degeneration - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Wet Age-Related Macular Degeneration - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Wet Age-Related Macular Degeneration - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Wet Age-Related Macular Degeneration - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
15 WET AGE-RELATED MACULAR DEGENERATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 WET AGE-RELATED MACULAR DEGENERATION MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 WET AGE-RELATED MACULAR DEGENERATION - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 WET AGE-RELATED MACULAR DEGENERATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 WET AGE-RELATED MACULAR DEGENERATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 WET AGE-RELATED MACULAR DEGENERATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Wet Age-Related Macular Degeneration Guidelines, Management and Treatment
8.2 Wet Age-Related Macular Degeneration Treatment Algorithm
9 WET AGE-RELATED MACULAR DEGENERATION - UNMET NEEDS
10 WET AGE-RELATED MACULAR DEGENERATION - KEY ENDPOINTS OF TREATMENT
11 WET AGE-RELATED MACULAR DEGENERATION - MARKETED PRODUCTS
11.1 List of Wet Age-Related Macular Degeneration Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 WET AGE-RELATED MACULAR DEGENERATION - PIPELINE DRUGS
12.1 List of Wet Age-Related Macular Degeneration Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. WET AGE-RELATED MACULAR DEGENERATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 WET AGE-RELATED MACULAR DEGENERATION - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Wet Age-Related Macular Degeneration - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Wet Age-Related Macular Degeneration - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Wet Age-Related Macular Degeneration - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Wet Age-Related Macular Degeneration - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Wet Age-Related Macular Degeneration - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Wet Age-Related Macular Degeneration - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Wet Age-Related Macular Degeneration - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Wet Age-Related Macular Degeneration - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
15 WET AGE-RELATED MACULAR DEGENERATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 WET AGE-RELATED MACULAR DEGENERATION MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
